The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
News|Articles|May 6, 2025
Endocrinology Month in Review: April 2025
Author(s)HCPLive Editorial Staff
Fact checked by: Connor Iapoce
Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.
Advertisement
Advertisement
April brought a wave of momentum in
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
Advertisement
Advertisement